Current Edition

anti-CGRP

Biohaven’s Nurtec, with dual migraine approvals, hits $136M in quarterly sales and leads the pack in market share

Biohaven’s migraine drug Nurtec ODT has been on a roll since becoming the first medicine to win a dual FDA approval to both treat and …

Continue Reading →